Please assess the completion status of the following clinical trial:

Trial Title: Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has severe or moderately severe hemophilia A as defined by a baseline factor VIII level \<= 2% of normal, as tested at screening~* The subject has a documented history of at least 150 exposure days to factor VIII concentrates (either plasma-derived or recombinant)~* The subject is within 7 to 65 years of age~* The subject has a Karnofsky performance score \> (greater than) 60~* The subject is human immunodeficiency virus negative (HIV-) or is HIV+ with a CD4 count \>= 400 cells/mm³ (CD4 count determined at screening, if necessary)~* The subject has been on a documented on-demand treatment regimen for at least 12 months immediately prior to enrollment~* The subject has a documented history (e.g. in medical charts or dispensing information, or signed investigator statement) of at least 8 joint hemorrhages in the 12 months immediately prior to enrollment~* The subject resides within the coverage area of the mobile compliance device; coverage area will be determined at screening~* The subject or the subject's legally authorized representative has provided written informed consent~Exclusion Criteria:~* The subject has a known hypersensitivity to factor VIII concentrates or mouse or hamster proteins~* The subject has a history of factor VIII inhibitors with a titer \>= 0.6 BU (by Bethesda or Nijmegen assay) at any time prior to screening~* The subject has a detectable factor VIII inhibitor at screening, with a titer \>= 0.4 BU (by Nijmegen Assay) in the central laboratory~* The subject has severe chronic liver disease as evidenced by, but not limited to, any of the following: International Normalized Ratio (INR) \> 1.4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices.~* The subject has been diagnosed with an inherited or acquired hemostatic defect other than hemophilia A (e.g., qualitative platelet defect or von Willebrand's Disease)~* The subject has been treated during the last sixty (60) days prior to or is being treated at screening/enrollment with an immunomodulating drug.~* The subject has participated in another investigational study within thirty (30) days of enrollment~* The subject has previously participated in a clinical study with rAHF-PFM~* The subject's clinical condition may require a major surgery (defined as moderate to critical risk and perioperative blood loss ≥ 500 mL) during the period of the subject's participation in the study~* The subject is female of childbearing potential with a positive pregnancy test

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Standard prophylaxis
- 2 (Type: EXPERIMENTAL): PK-driven prophylaxis

Based on this trial design, predict the completion outcome and termination type (if applicable).